Status:
COMPLETED
Evaluation of the Predictive and Prognostic Value of Germ-line Polymorphisms in Patients With Metastatic Breast Cancer
Lead Sponsor:
Centre Leon Berard
Collaborating Sponsors:
Centre de Recherche en Cancérologie de Lyon
Conditions:
Breast Cancer
Metastasis
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
This is a multicenter, non-randomized, prospective cohort study. The purpose of the study is to identify germ line genetic factors that influence the risk of metastatic breast cancer. 1500 patients w...
Detailed Description
The StoRM trial is designed for analysis in association with the SIGNAL study which aims to decipher the genetic risk of breast cancer displaying amplification of the HER2 gene as well as resistance o...
Eligibility Criteria
Inclusion
- Women with a histologically proven breast adenocarcinoma, with metastatic progression diagnosed within one year (inclusion of patients who have a metastatic progression more than one year ago would favor the inclusion of patients with indolent cancer, possibly biasing the study) or locally advanced (no curative treatment)
- ER, PR and HER2 status known
- Age \>= 18 years
- Affiliation with a social security scheme
- Signed informed consent
Exclusion
- Coexisting or other cancer diagnosed within the previous 5 years that may be responsible for the current metastasis
- Patient who cannot follow medical surveillance due to geographical, social or psychological reasons
- Patient included in the SIGNAL study
Key Trial Info
Start Date :
December 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2017
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT01460186
Start Date
December 1 2011
End Date
September 1 2017
Last Update
January 15 2019
Active Locations (17)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Jean Minjoz - CHU Besançon
Besançon, France, 25030
2
Institut Bergonié
Bordeaux, France, 33000
3
Centre François Baclesse
Caen, France, 14000
4
Centre Georges François Leclerc
Dijon, France, 21079